Company intelligence / Profile preview

Processa Pharmaceuticals, Inc.

Hanover, Maryland, United Statesprocessapharmaceuticals.com ↗

Ownership: Public · PCSA
Employees: ~11-50
Development stage: Phase 2

Overview

Processa's lead candidate NGC-Cap is in Phase 2 clinical trials for metastatic breast cancer with initial data readout expected in mid-2025. NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity. Preclinical studies for NGC-Iri showed it delivers more cancer-killing SN-38 molecules to tumors than either irinotecan or Onivyde.

Therapeutic areas: GastroenterologyOncologyDermatology
Modalities: Small moleculesNext Generation Chemotherapy (NGC)
Industry: Biotech

Drug pipeline

8 assets

PCS-499

7 more assets in the full pipeline.

Request access →

Financials

Market cap: $5.5M
Total revenue: $0
Enterprise value: $5.3M

Beyond the preview

Go deeper on Processa Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Processa Pharmaceuticals, Inc..

Explore the full profile